MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fendo.2025.1574392

Медицинская библиотека · Frontiers in endocrinology · 2025

Molecular and clinical profiles of T2DM, dyslipidemia, and periodontitis: insights into inflammatory and metabolic dysregulation.

Okoro Peace Ngozi, Ambrose George Oche, Obaro Victor Emmanuel, Ugwueze Chidiebere Valentine, Olarinoye J K, Agede Olalekan A

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Type 2 Diabetes Mellitus (T2DM), dyslipidemia, and periodontitis are interconnected conditions that exacerbate systemic inflammation and metabolic dysregulation. Understanding the molecular and clinical profiles of these comorbidities is crucial for developing targeted interventions. This study investigates the molecular and clinical profiles of individuals with T2DM, dyslipidemia, and periodontitis to identify key markers and pathways underlying disease severity and progression.

METHODS

Peripheral blood mononuclear cells (PBMCs) were analyzed from five patient groups: T2DM poorly controlled with dyslipidemia and periodontitis (T2DMpoorly-DLP-H), T2DM well-controlled with dyslipidemia and periodontitis (T2DMwell-DLP-H), dyslipidemia and periodontitis (DL-P), periodontitis alone (P), and healthy controls (H). Correlations between molecular and clinical markers were assessed.

RESULTS

The T2DMpoorly-DLP-H group exhibited the most extensive molecular dysregulation, including unique upregulation of Plasminogen Activator, Tissue Type (PLAT) and consistent overexpression of Vanin-1 (VNN1), a key regulator of oxidative stress. HbA1c and fasting plasma glucose were highest in this group (HbA1c >12%, glucose >300 mg/dL), correlating strongly (R² = 0.88, p < 0.001). In contrast, the T2DMwell-DLP-H group demonstrated reduced gene dysregulation and improved glycemic control (HbA1c ~6.5%). Sex-specific differences were observed, with females exhibiting higher glycemic markers (p = 0.014) and males showing elevated lipid levels (p = 0.021).

DISCUSSION: This study identifies Vanin-1 (VNN1) as a potential biomarker for systemic inflammation and highlights the role of Plasminogen Activator, Tissue Type (PLAT) in vascular dysfunction, emphasizing the critical importance of glycemic control in mitigating molecular and clinical dysregulation. These findings underscore the need for personalized, sex-specific strategies to manage these comorbidities effectively.

Для цитирования: Okoro Peace Ngozi, Ambrose George Oche, Obaro Victor Emmanuel, Ugwueze Chidiebere Valentine, Olarinoye J K, Agede Olalekan A. Molecular and clinical profiles of T2DM, dyslipidemia, and periodontitis: insights into inflammatory and metabolic dysregulation.. Frontiers in endocrinology. 2025. DOI: 10.3389/fendo.2025.1574392.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.